{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 194,
  "pageCount": 239,
  "prevPage": 193,
  "nextPage": 195,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses expert testimony to contradict potential growth narratives, specifically highlighting a $5,000 price erosion per device.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/194",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-194",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "discounting is part of Nevro's approach now",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b347-29e920b91da1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "list",
      "text": "The ex-executive stated that while Omnia is a flop and Grossman is over-rated. Nevro's biggest issue is that they've begun heavily discounting their stimulators and that it's a price war with Medtronic. Abbott, and Boston Scientific",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ea15e7e-9d23-4e91-b0d3-cd9128d7abd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "list",
      "text": "The ex-executive indicated that stimulator prices dropped a stunning $5,000, or roughly -20%, and that \"discounting is part of Nevro's approach now\"",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a03bedb0-61e5-432a-8d37-fd4a9cb97b30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "price erosion: -20%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b347-30b8c22cf3fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "A former Nevro executive corroborated the price war. He offered extensive insights into Nevro's pricing predicament and how it dooms any \"turnaround.\" He stated that \"discounting is part of Nevro's approach now.\"",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c9d33af-cd60-4408-8bcd-5f01a453a45c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.08,
        "y": 0.28
      },
      "kind": "quote",
      "text": "\"I think it's highly over-valued... Omnia is an overpriced product... they never got any kind of pop on Omnia... it's a price war.\" - Former Nevro executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27bc6758-9bf4-44f1-aedb-f6b9ae36b34e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.08,
        "y": 0.47
      },
      "kind": "quote",
      "text": "\"A great question that you should always ask every physician... what are you paying for a battery this year over last year? And you see erosion in price... about $5k in price erosion annually... discounting is part of Nevro's approach now.\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e4d383d-1e4a-4584-b83b-47f4bb73dd74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "I think it’s highly over-valued. And I would say, not only the stock but the company, Omnia, and also Grossman....an outsider looks at what he’s trying to do and says, wow that’s pretty impressive. However, Omnia is an overpriced product and I don’t see it saving the day. And the reason they’re not growing is that they never got an impact from Omnia. What really caught them was that they discounted their pricing heavily on their other product line, so they never got any kind of pop on Omnia. Abbott and their other key competitors are also not doing well, and so, it’s a price war. — Former Nevro executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b347-2c6c541f8d60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0eb8a09-8b29-4484-bc78-2601e1a31d3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "15. Pricing pressure and discounting are a key driver of Nevro's collapse and doom any return to growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c4d01ff-44fb-44b3-abd0-a55edd984a29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b835fb3-a15d-4a58-aa85-10dd088250d1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "b1876c41-6d2b-461d-a49f-55c8ae5dc01e",
      "evidence": "Uses former executive quotes to directly contradict company growth claims.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}